Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Frontiers in Neuroscience Seminar Series

April 22, 16:30 

Portrait photo of Jonathan Whitlock.

Jonathan Whitlock
Kavli Institute for Systems Neuroscience, Norwegian University of Science and Technology in Trondheim, Norway. 

"Neural tuning to 3D pose and movement: a universal feature of cortical processing?"

Short presentation of the speaker:
Jonathan Whitlock is an associate professor of neuroscience at the Kavli Institute for Systems Neuroscience in Trondheim, Norway. His group combines high-density single-unit recordings with silicone probes and sub-millimeter 3D tracking to study the cortical representation of pose and movement in freely behaving rats. The lecture will include the group’s recent findings of postural tuning occurring across primary cortical areas— including primary visual, auditory, somatosensory and motor cortices.

The lecture will take place via Zoom (contact diana [dot] jerman [at] med [dot] lu [dot] se for link). 
Host: Angela Cenci Nilsson

May 20, 16:00

Portrait photo of Michael Egan.

Michael F. Egan, MD
Vice President,  Neuroscience and Ophthalmology
Global Clinical Development, Merck Research Laboratories

"Drug development challenges in Alzheimer’s disease"

Short presentation of the speaker:
Michael F. Egan, MD  Vice President, Clinical Neuroscience. Dr. Egan received his BA from the University of Virginia and his medical degree from the University of Maryland. Following residency at the University of Colorado, he completed a research fellowship at the NIMH in Neuropsychiatry.   In 1996 Dr. Egan joined the Clinical Brain Disorders Branch at NIMH as a principle investigator focused on the genetics of schizophrenia and cognition. Dr. Egan joined Merck in 2005 and led clinical trials for a variety of neuropsychiatric disorders, including the BACE inhibitor, verubecestat.  He is currently Vice President, Global Clinical Development in Neuroscience at Merck.

The lecture will take place via Zoom (contact diana [dot] jerman [at] med [dot] lu [dot] se for link). 
Host: Niklas-Mattsson-Carlgren


Angela [dot] Cenci_Nilsson [at] med [dot] lu [dot] se (Angela Cenci-Nilsson), Gunnar [dot] Gouras [at] med [dot] lu [dot] se (Gunnar Gouras)Oskar [dot] Hansson [at] med [dot] lu [dot] se (Oskar Hansson)per [dot] odin [at] med [dot] lu [dot] se (Per Odin)